|
1.
|
Thompson L, Wang S, Tawfik O, et al:
Effect of 25-hydroxyvitamin D3 and 1 α,25 dihydroxyvitamin D3 on
differentiation and apoptosis of human osteosarcoma cell lines. J
Orthop Res. 30:831–844. 2012.
|
|
2.
|
Chugh R: Experimental therapies and
clinical trials in bone sarcoma. J Natl Compr Canc Netw. 8:715–725.
2010.PubMed/NCBI
|
|
3.
|
Dai X, Ma W, He X, et al: Review of
therapeutic strategies for osteosarcoma, chondrosarcoma, and
Ewing’s sarcoma. Med Sci Monit. 17:RA177–190. 2011.
|
|
4.
|
Kagan HM and Trackman PC: Properties and
function of lysyl oxidase. Am J Respir Cell Mol Biol. 5:206–210.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Kim YM, Kim EC and Kim Y: The human lysyl
oxidase-like 2 protein functions as an amine oxidase toward
collagen and elastin. Mol Biol Rep. 38:145–149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Bais MV, Nugent MA, Stephens DN, et al:
Recombinant lysyl oxidase propeptide protein inhibits growth and
promotes apoptosis of pre-existing murine breast cancer xenografts.
PLoS One. 7:e311882012. View Article : Google Scholar
|
|
7.
|
Palamakumbura AH, Vora SR, Nugent MA, et
al: Lysyl oxidase propeptide inhibits prostate cancer cell growth
by mechanisms that target FGF-2-cell binding and signaling.
Oncogene. 28:3390–3400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hurtado PA, Vora S, Sume SS, et al: Lysyl
oxidase propeptide inhibits smooth muscle cell signaling and
proliferation. Biochem Biophys Res Commun. 366:156–161. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Erler JT, Bennewith KL, Nicolau M, et al:
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature.
440:1222–1226. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kirschmann DA, Seftor EA, Fong SF, et al:
A molecular role for lysyl oxidase in breast cancer invasion.
Cancer Res. 62:4478–4483. 2002.PubMed/NCBI
|
|
11.
|
Baker AM, Bird D, Lang G, et al: Lysyl
oxidase enzymatic function increases stiffness to drive colorectal
cancer progression through FAK. Oncogene. 73:583–594.
2013.PubMed/NCBI
|
|
12.
|
Lapointe J, Li C, Higgins JP, et al: Gene
expression profiling identifies clinically relevant subtypes of
prostate cancer. Proc Natl Acad Sci USA. 101:811–816. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Wu J, Cai C, Tong D, et al: Lysyl oxidase
G473A polymorphism is associated with increased risk of ovarian
cancer. Genet Test Mol Biomarkers. 16:915–919. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Stassar MJ, Devitt G, Brosius M, et al:
Identification of human renal cell carcinoma associated genes by
suppression subtractive hybridization. Br J Cancer. 85:1372–1382.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Giampuzzi M, Botti G, Cilli M, et al:
Down-regulation of lysyl oxidase-induced tumorigenic transformation
in NRK-49F cells characterized by constitutive activation of ras
proto-oncogene. J Biol Chem. 276:29226–29232. 2001. View Article : Google Scholar
|
|
16.
|
Bouez C, Reynaud C, Noblesse E, et al: The
lysyl oxidase LOX is absent in basal and squamous cell carcinomas
and its knockdown induces an invading phenotype in a skin
equivalent model. Clin Cancer Res. 12:1463–1469. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Barker HE, Cox TR and Erler JT: The
rationale for targeting the LOX family in cancer. Nat Rev Cancer.
12:540–552. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Novello C, Pazzaglia L, Cingolani C, et
al: miRNA expression profile in human osteosarcoma: role of miR-1
and miR-133b in proliferation and cell cycle control. Int J Oncol.
42:667–675. 2013.PubMed/NCBI
|
|
19.
|
Sollazzo MR, Benassi MS, Magagnoli G, et
al: Increased c-myc oncogene expression in Ewing’s sarcoma:
correlation with Ki67 proliferation index. Tumori. 85:167–173.
1999.
|
|
20.
|
Li B, Yang Y, Jiang S, et al:
Adenovirus-mediated overexpression of BMP-9 inhibits human
osteosarcoma cell growth and migration through downregulation of
the PI3K/AKT pathway. Int J Oncol. 41:1809–1819. 2012.PubMed/NCBI
|
|
21.
|
Liu ZL, Wang G, Peng AF, et al: Fatty acid
synthase expression in osteosarcoma and its correlation with
pulmonary metastasis. Oncol Lett. 4:878–882. 2012.PubMed/NCBI
|
|
22.
|
Kamei S, Sakayama K, Tamashiro S, et al:
Ketoprofen in topical formulation decreases the matrix
metalloproteinase-2 expression and pulmonary metastatic incidence
in nude mice with osteosarcoma. J Orthop Res. 27:909–915. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Duan DP, Dang XQ, Wang KZ, et al: The
cyclooxygenase-2 inhibitor NS-398 inhibits proliferation and
induces apoptosis in human osteosarcoma cells via downregulation of
the survivin pathway. Oncol Rep. 28:1693–1700. 2012.PubMed/NCBI
|
|
24.
|
Korpi JT, Hagstrom J, Lehtonen N, et al:
Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue
inhibitors of metalloproteinase-1 in human osteosarcoma. Surg
Oncol. 20:e18–e22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Zhang Y, Song L, Cai L, et al: Effects of
baicalein on apoptosis, cell cycle arrest, migration and invasion
of osteosarcoma cells. Food Chem Toxicol. 53C:325–333.
2012.PubMed/NCBI
|
|
26.
|
Rasmussen N and Rathmell WK: Looking
beyond inhibition of VEGF/mTOR: emerging targets for renal cell
carcinoma drug development. Curr Clin Pharmacol. 6:199–206. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Kubista B, Klinglmueller F, Bilban M, et
al: Microarray analysis identifies distinct gene expression
profiles associated with histological subtype in human
osteosarcoma. Int Orthop. 35:401–411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Buchinger B, Spitzer S, Karlic H, et al:
Lysyl oxidase (LOX) mRNA expression and genes of the differentiated
osteoblastic phenotype are upregulated in human osteosarcoma cells
by suramin. Cancer Lett. 265:45–54. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Payne SL, Fogelgren B, Hess AR, et al:
Lysyl oxidase regulates breast cancer cell migration and adhesion
through a hydrogen peroxide-mediated mechanism. Cancer Res.
65:11429–11436. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Gacheru SN, Thomas KM, Murray SA, et al:
Transcriptional and post-transcriptional control of lysyl oxidase
expression in vascular smooth muscle cells: effects of TGF-beta 1
and serum deprivation. J Cell Biochem. 65:395–407. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Peinado H, Moreno-Bueno G, Hardisson D, et
al: Lysyl oxidase-like 2 as a new poor prognosis marker of squamous
cell carcinomas. Cancer Res. 68:4541–4550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Yu Z, Sato S, Trackman PC, et al: Blimp1
activation by AP-1 in human lung cancer cells promotes a migratory
phenotype and is inhibited by the lysyl oxidase propeptide. PLoS
One. 7:e332872012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Palamakumbura AH, Jeay S, Guo Y, et al:
The propeptide domain of lysyl oxidase induces phenotypic reversion
of ras-transformed cells. J Biol Chem. 279:40593–40600. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Hotfilder M, Sondermann P, Senss A, et al:
PI3K/AKT is involved in mediating survival signals that rescue
Ewing tumour cells from fibroblast growth factor 2-induced cell
death. Br J Cancer. 92:705–710. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Liu B, Shi ZL, Feng J, et al: Celecoxib, a
cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma
cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int.
32:494–501. 2008. View Article : Google Scholar
|
|
36.
|
Jin S, Pang RP, Shen JN, et al: Grifolin
induces apoptosis via inhibition of PI3K/AKT signalling pathway in
human osteosarcoma cells. Apoptosis. 12:1317–1326. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Jeay S, Pianetti S, Kagan HM, et al: Lysyl
oxidase inhibits ras-mediated transformation by preventing
activation of NF-kappa B. Mol Cell Biol. 23:2251–2263. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Pez F, Dayan F, Durivault J, et al: The
HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway
in a positive regulation loop and synergizes with HIF-1 in
promoting tumor cell growth. Cancer Res. 71:1647–1657. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Voloshenyuk TG, Landesman ES, Khoutorova
E, et al: Induction of cardiac fibroblast lysyl oxidase by
TGF-beta1 requires PI3K/Akt, Smad3, and MAPK signaling. Cytokine.
55:90–97. 2011. View Article : Google Scholar : PubMed/NCBI
|
